News
Cristal Therapeutics Starts Clinical Phase I Trial with Nanomedicine CriPec® Docetaxel in Patients with Solid Tumours
Cristal Therapeutics, a privately-held life sciences company developing innovative drugs against cancer and other diseases, today announced the recent start of a clinical phase I trial with its lead candidate CriPec® docetaxel in patients with solid tumours.Health~Holland launches online portal
Under the flag of Health~Holland, the Top Sector Life Sciences & Health (LSH) aims to connect and support innovative organisations active in the Dutch LSH sector. This user-friendly online gateway serves as the central information hub for life sciences and health SMEs and other organisations in the Netherlands and internationally.
Aduro Biotech acquires BioNovion
Aduro Biotech, Inc. and BioNovion Holding B.V. announced that they have entered into a definitive agreement for Aduro to acquire BioNovion, a privately held monoclonal antibody discovery and development company based in The Netherlands.Kinesis Pharma and Venn Life Sciences will join forces
Kinesis Pharma (Kinesis) and Venn Life Sciences (Venn) will join forces in offering drug development services to the pharmaceutical and biotech industry as well as to investors in these areas. The companies have entered into an agreement under which Venn will acquire the entire issued share capital of Kinesis.Pan-European APPROACH project receives 15 million Euro research funding to find the right osteoarthritis medicine for the right patient
In a bid to stimulate the development of much needed treatments for osteoarthritis, a consortium of 24 partners comprising pharmaceutical companies, biotech companies, academic institutions, not-for-profit organizations, small and medium enterprises (SMEs) and public bodies have joined forces in the pan-European APPROACH (Applied Public-Private Research enabling OsteoArthritis Clinical Headway) project, with total research funding of 15 million Euros.Amgen to Aquire Privately-held Dezima Pharma
Amgen (NASDAQ:AMGN) and Dezima Pharma B.V. (Dezima) announced that the companies have entered into a definitive acquisition agreement under which Amgen will acquire Dezima, a privately-held, Netherlands-based biotechnology company focused on developing innovative treatments for dyslipidemia. Dezima shareholders have approved the agreement.Barend Mons appointed Chair of European Commission’s high level expert group on ‘European Open Science Cloud’
Professor Barend Mons has been appointed Chair of the Commission High Level Expert Group "European Open Science Cloud", initiated by the European Commission, DG Research and Innovation.Kite Pharma Expands Collaboration With Netherlands Cancer Institute (NKI)
Kite Pharma announced that it has expanded its collaboration with the Netherlands Cancer Institute (NKI). Kite and the NKI have entered into an agreement under which Kite will receive from the NKI the exclusive option to license multiple T cell receptor (TCR) gene sequences for the development and commercialization of cancer immunotherapy candidates targeting solid tumors.New publication: Health~Holland Guide 2015-2016
The Task Force Health Care and Health~Holland present the third edition of the Health~Holland Guide.